

USSN: 10/016,969

Amdt. Dated September 30, 2003

Reply to Office Action of June 18, 2003

**REMARKS/ARGUMENTS***Status of the Claims*

Claims 1,8, and 33 to 51 were pending. In the instant Supplemental Amendment, Applicants have amended claims 33, 38 to 42, 45 to 48, and 51; and introduced new claims 52-54. Therefore, with the entry of the present amendments, claims 1, 8, 33-55 are currently pending in the application.

Support for new claims 52 and 53 can be found at least at page 5, lines 25-27; page 7, lines 13-16; Example 6; and page 7, line 23, to page 8, line 4 (where the use of PYY or PYY agonist is combined with other compounds for reducing nutrient availability to increase weight loss). Support for new claim 52 directed to routes of delivering the PYY or PYY agonist can be found at least at page 13, lines 4-8. Claims 33, 38 to 42, 45 to 48, and 51 have been amended to correct typographical error and/or to introduce dependencies to the new claims. Applicants submit that no new matter has been introduced into the currently pending claims.

Claims 52 and 53 are patentable for the reasons provided in the previously filed response of September 22, 2003. None of the references provide an enabling disclosure to teach or suggest to one of ordinary skill in the art that peripherally administering PYY or a PYY agonist could reduce weight, reduce weight gain, or increase weight loss. Claim 54 is a dependent claim that incorporates all the limitations of the independent claims to which it depends. Therefore, for at least the reasons provided in the previously submitted Sept. 22<sup>nd</sup> Response as to why claims 1, 8, and 33-51 are patentable, Applicants submit that claims 52-54 are patentable as well.


Applicants respectfully submit that the claims are now in condition for allowance and request that a timely Notice of Allowance be issued in this case. The Examiner is encouraged to call the undersigned attorney to discuss any issues related to the prosecution of the instant application.

Applicants believe that except for the excess claims fees for which authorization to charge the deposit account is provided, no other fee is necessitated by the present paper.

USSN: 10/016,969  
Amdt. Dated September 30, 2003  
Reply to Office Action of June 18, 2003

However, in the event any other fee is due or an amount is to be credited, Applicants authorize the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Respectfully submitted,

 9/30/2003

Mi K. Kim  
Reg. No. 44,830

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Phone: (858) 552-2200  
Facsimile: (858) 552-1936